
    
      Non-interventional study based on newly collected data. The study will consist of a baseline
      visit and follow-up visits at Week 4, 8, 12, 24, 36 and 52 for patients who have newly
      initiated Micatrio® Combination Tablets. The patients will be followed up until
      discontinuation of Micatrio® Combination Tablets treatment or the end of study.

      All patients administrated Micatrio® Combination Tablets after the launch at the sites
      contracted with the sponsor will be registered.
    
  